Connect your AI

Travere Therapeutics, Inc. TVTX Price / book

Price / book at other companies

Vertex PharmaceuticalsVRTX

5.9×-1.7×

LQD

Liquidia CorporationLQDA

30.6×+5.3×

Arrowhead ResearchARWR

14.3×+11.7×

Scholar RockSRRK

20.5×+10.7×

Protagonist TherapeuticsPTGX

10.3×+6.0×

United TherapeuticsUTHR

4.4×+2.4×

Other financials

Income statement

Revenue$127.2M+55.6%

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

Market cap$5.13B+72.3%

Enterprise value$5.07B+65.5%

P/S9.6×-1.3×

Profitability

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Calculated from Travere Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=27.8×

Based on the most recent quarter.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Travere Therapeutics, Inc.'s price / book?: Travere Therapeutics, Inc. (TVTX) reported price / book of 27.8× in Q1 2026.
How has Travere Therapeutics, Inc.'s price / book changed year-over-year?: Travere Therapeutics, Inc.'s price / book decreased by 42.7% year-over-year, from 48.4× to 27.8×.
What is the long-term trend for Travere Therapeutics, Inc.'s price / book?: Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s price / book has grown at a 32.6% compound annual growth rate (CAGR), from 7.3× to 29.8×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.